

# Anti-IL-6 (Interleukin-6) / Interferon beta-2 (Hybridoma Growth Factor) Monoclonal Antibody

Catalog Number: M00102

#### Introduction

The clone MYG13 recognizes CD22 cell surface antigen, a 130-140kDa protein. The expression of CD22 is primarily restricted to the normal and neoplastic B cells but does not express on other hematopoietic cells. The initiation of expression of CD22 starts in the cytoplasm of pro-B and pre-B cells. Although CD22 is not expressed by plasma cells, it is abundantly expressed by the follicular mantle and marginal zone B-cells. Being a member of the immunoglobulin superfamily, CD22 serves as an adhesion receptor for sialic acid-bearing ligands expressed on erythrocytes and leukocytes. The role of CD22 in the activation of B-cells is primarily associated with tyrosine kinases mediated signal transduction pathways.

This antibody is routinely tested by flow cytometric analysis. Flow cytometry and other applications were tested during antibody development by CapricoBio or are reported in the literature.

### **Application Information**

Each lot of this antibody has been pre-titrated and tested by flow cytometric analysis of human PBMCs such that 5ul of this product is sufficient for staining of 1 million cells in a 100ul staining volume or 100ul of whole blood. It is recommended that antibody reactivity be empirically titrated for optimal performance in the application of interest.

#### **About IL6**

This monoclonal antibody specifically precipitates heterogeneous material of high MW, identified as perlecan, a major heparan-sulfate proteoglycan (HSPG) within all basement membranes and cell surfaces. It does not cross-react with laminin, fibronectin, or dermatran sulfate proteoglycan. Because of perlecan's strategic location and ability to store and protect growth factors, it has been strongly implicated in the control of tumor cell growth and metastatic behavior. Perlecan possesses angiogenic and growth-promoting attributes primarily by acting as a co-receptor for basic fibroblast growth factor (FGF-2). Suppression of perlecan causes substantial inhibition of neoplastic growth and neovascularization. Thus, perlecan is a potent inducer of neoplasm growth and angiogenesis in vivo and therapeutic interventions targeting this key modulator of tumor progression may improve neoplastic treatment.

#### Overview

Product Name	Anti-IL-6 (Interleukin-6) / Interferon beta-2 (Hybridoma Growth Factor) Monoclonal Antibody
Reactive Species	Human, Mouse
Description	Boster Bio Anti-IL-6 (Interleukin-6) / Interferon beta-2 (Hybridoma Growth Factor) Monoclonal Antibody catalog # M00102. Tested in IHC applications. This antibody reacts with Human, Mouse.
Conjugate	APC
Application	IHC
Clonality	Monoclonal IL6/1270




Formulation	Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.
Storage Instructions	Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.
Host	Rat
Uniprot ID	P05231

## **Technical Details**

Immunogen	Recombinant IL-6 protein
Predicted Reactive Species	Bovine
Isotype	IgG2a, kappa
Form	Liquid
Concentration	0.5-1mg/ml, actual concentration vary by lot. Use suggested dilution ratio to decide dilution procedure.
Purification	200ug/ml of antibody purified from Bioreactor Concentrate by Protein A/G.
Suggested Dilutions	Dilute the sample so that the expected range of concentrations fall within the detection range of this kit.  If the expected range of concentration is unknown, a pilot test should be conducted to decide the optimal dilution ratio for your samples.  Some PubMed article(s) citing the expression level of this target are as follows:  Boster Bio's internal QC testing used:  Immunohistology (Formalin-fixed) (1-2ug/ml for 30 minutes at RT)  Immunofluorescence (0.5-1ug/ml)



## Anti-IL-6 (Interleukin-6) / Interferon beta-2 (Hybridoma Growth Factor) Monoclonal Antibody (M00102) Images



Formalin-fixed, paraffin-embedded human Colon Carcinoma stained withIL-6 Monoclonal Antibody (IL6/1270).

## 16 Publications Citing This Product

- 1. PubMed ID: 24603891, Sun W, Liu Db, Li Ww, Zhang Ll, Long Gx, Wang Jf, Mei Q, Hu Gq. Int J Oncol. 2014 May;44(5):1551-60. Doi: 10.3892/Ijo.2014.2323. Epub 2014 Mar 5. Interleukin-6 Promotes The Migration And Invasion Of Nasopharyngeal Carcinoma Cell Lines And Upregula...
- 2. PubMed ID: 26990441, Inhibition of Acute Lung Injury by TNFR-Fc through Regulation of an Inflammation-Oxidative Stress Pathway
- 3. PubMed ID: 27463015, Potential implications of Apolipoprotein E in early brain injury after experimental subarachnoid hemorrhage: Involvement in the modulation of blood-brain barrier integrity

Visit bosterbio.com/anti-il-6-interleukin-6-interferon-beta-2-hybridoma-growth-factor-antibody-m00102-boster.html to see all 16 publications.

## Submit a product review to Biocompare.com





Submit a review of this product to Biocompare.com to receive a \$20 Amazon.com giftcard! Your reviews help your fellow scientists make the right decisions. Thank you for your contribution.

Anti-IL-6 (Interleukin-6) / Interferon beta-2 (Hybridoma Growth Factor) Monoclonal Antibody